Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12779413 | 0.90 | MEN1 (0.47) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL14199913 | 0.88 | MEN1 (0.53) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL12778251 | 0.84 | MEN1 (0.47) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL14199911 | 0.83 | MEN1 (0.43) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12779412 | 0.82 | SENP5 (0.49) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL12253970 | 0.81 | PTPN1 (0.47) | MEN1KMT2AMAPTSMN1; SMN2PKM | |
| SCHEMBL14450789 | 0.77 | HPGD (0.47) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14199914 | 0.77 | HPGD (0.47) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12253971 | 0.77 | ALDH1A1 (0.46) | KMT2AMAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL14199912 | 0.76 | HPGD (0.46) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | MEN1 4301/4885KMT2A 2424/4885MAPT 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.